RecruitingPhase 4NCT07600177

Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy

Sponsor

Oregon Health and Science University

Enrollment

40 participants

Start Date

May 5, 2026

Study Type

INTERVENTIONAL

Conditions

Hypertrophic Cardiomyopathy (HCM)

Summary

This is an investigator-initiated two-center study. The goal of this study is to investigate the feasibility, safety and efficacy outcomes of a seamless transition from mavacamten to aficamten in patients with obstructive hypertrophic cardiomyopathy (oHCM).

Eligibility

Min Age: 18 YearsMax Age: 90 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Aficamten for people with hypertrophic cardiomyopathy (hcm). The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years to 90 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.